Regenxbio (RGNX) Revenue (2014 - 2026)

Regenxbio's Revenue history runs 12 years deep, the most recent figure standing at $27.1 million for Q4 2025.

• In Q4 2025, Revenue rose 27.97% year-over-year to $27.1 million; the TTM figure through Dec 2025 stood at $165.3 million (up 100.11% YoY), while the FY2025 annual figure was $156.3 million, up 87.53% from the prior year.
• Revenue for Q4 2025 stood at $27.1 million, down from $29.7 million in the prior quarter.
• The five-year high for Revenue was $398.7 million in Q4 2021, with the low at $15.3 million in Q1 2024.
• The 5-year median for Revenue is $23.2 million (2022), against an average of $46.1 million.
• The sharpest annual moves came in 2021 and 2022: Revenue soared 1758.96% in 2021, then sank 92.14% in 2022.
• Regenxbio's Revenue stood at $398.7 million in 2021, then tumbled by 92.14% to $31.3 million in 2022, then slipped by 29.13% to $22.2 million in 2023, then retreated by 4.5% to $21.2 million in 2024, then climbed by 27.97% to $27.1 million in 2025.
• Business Quant data shows RGNX's Revenue at $27.1 million in Q4 2025, $29.7 million in Q3 2025, and $21.4 million in Q2 2025.